Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2 CYP2C9 CYP2C19 and CYP3A4

    Not Recruiting
  • End date
    Oct 9, 2022
  • participants needed
  • sponsor
    R-Pharm International, LLC
Updated on 2 June 2022
body mass index
folic acid


Olokizumab (OKZ) has been shown to reverse the inhibitory effect of IL-6 on the activity of Cytochrome P450 (CYP450) isozymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5 in vitro.

The goal of the study is to assess the effect of OKZ on the pharmacokinetics (PK) of the CYP450 probe substrates, caffeine (CYP1A2), S-warfarin (CYP2C9), omeprazole (CYP2C19), and midazolam (CYP3A4) in subjects with rheumatoid arthritis (RA).


This is a Phase 1, open-label, 3-period, single-sequence, crossover study in subjects with RA with increased C-reactive protein (CRP).

Approximately 15 eligible subjects will be enrolled at approximately 3 study centers to have at least 12 evaluable subjects completing the study. However, if necessary, additional subjects may be dosed to obtain the 12 evaluable subjects required.

There will be a 35-day Screening Period, followed by a 29-day study duration: eligible patients will be administered a cocktail of 4 substrates alone during 7-day PK-sampling (Period 1); a single subcutaneous dose of 128 mg OKZ will be administered (Period 2) approximately 2 weeks prior to the second administration of the cocktail in 7-day PK-sampling (Period 3). After completion of the Period 3 patients will be followed-up for 19 weeks (133 days) for safety evaluations.

Overall duration of the study will be approximately 200 days (6 and a half months).

Condition Rheumatoid Arthritis, Rheumatoid Arthritis (Pediatric)
Treatment Midazolam, caffeine, Omeprazole, Olokizumab, Warfarin+ Vitamin K
Clinical Study IdentifierNCT04246762
SponsorR-Pharm International, LLC
Last Modified on2 June 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note